What's in Otsuka Pakistan Limited's pipeline?

Otsuka Pakistan Limited has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Otsuka Pakistan Limited's portfolio?

Top competitors by shared drug class: Otsuka Pharmaceutical, Inc., Philippines.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/otsuka-pakistan-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Otsuka Pakistan Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Otsuka Pakistan Limited pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Rebamipide and Omeprazole	Rebamipide and Omeprazole	phase 3	Mucoprotective agent + Proton pump inhibitor combination	Rebamipide: gastric mucosa protective pathways; Omeprazole: H+/K+-ATPase (proton pump)	Gastroenterology

Therapeutic area mix

Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Otsuka Pharmaceutical, Inc., Philippines · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Otsuka Pakistan Limited:

Cite this brief

Drug Landscape (2026). Otsuka Pakistan Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/otsuka-pakistan-limited. Accessed 2026-05-17.